tl;dr: Moderna and Merck's Phase 3 trial of intismeran autogene, an individualized mRNA neoantigen therapy, combined with Keytruda met its primary endpoint of recurrence-free survival in patients with resected stage IIB-IV melanoma, as well as a key secondary endpoint of distant metastasis-free survival. This is the first positive Phase 3 result for both an individualized neoantigen therapy and an mRNA-based cancer therapy.